30 Day Trial

Xtant Medical Enters Distribution Agreement with Vivex Biomedical for OsteoVive Cellular Allograft


Xtant Medical entered into a distribution relationship with Vivex Biomedical to commercialize OsteoVive™ viable cell allograft.

Vivex will process the allograft for Xtant's U.S. distribution, for use in spine and orthopaedic procedures.

Vivex Biomedical’s proprietary process preserves a cell population that includes marrow-isolated adult multilineage inducible (MIAMI) cells, which have demonstrated support for the innate bone healing process.

Source: Xtant Medical Holdings, Inc.


Xtant and Vivex were named in our 2015 coverage, NASS PREVIEW: A Guide to the Recently-merged in Spine.